Promises to revolutionize how drug discovery teams guide their studies
Biologists at the University of California, San Diego have developed a revolutionary new method for identifying and characterizing antibiotics, an advance that could lead to the discovery of new antibiotics to treat antibiotic resistant bacteria.
The researchers, who published their findings in this week’s early online edition of the journal Proceedings of the National Academy of Sciences, made their discovery by developing a way to perform the equivalent of an autopsy on bacterial cells.
“This will provide a powerful new tool for identifying compounds that kill bacteria and determining how they work,” said Joseph Pogliano, a professor of biology at UC San Diego who headed the research team. “Some bacteria have evolved resistance to every known class of antibiotic and, when these multi-drug resistant bacteria cause an infection, they are nearly impossible to treat. There is an urgent need for new antibiotics capable of treating infections caused by antibiotic resistant bacteria.”
The Centers for Disease Control and Prevention issued an alarming report in March that antibiotic-resistant strains of Carbapenem-Resistant Enterobacteriaceae, or CRE, had been found to cause infections in patients in nearly 200 hospitals in the United States alone. Because no antibiotics on the market are effective at treating these infections, about one-half of patients die from CRE infections. These outbreaks are difficult to contain, and in a 2011 outbreak of Klebsiella pneumonia at the U.S. National Institutes of Health Clinical Center, the bacteria spread despite strict infection control procedures and was detected in drains and medical devices that had been subject to standard decontamination protocols.
“We are finally running out of the miracle drugs,” said Pogliano, who detailed the history: The antibiotic penicillin was first discovered in the late 1920s, and received widespread clinical use in the 1940s. However, bacteria quickly evolved resistance to penicillin, so new and better versions were developed. Since that time, a continuous race has been fought to identify new antibiotics in order to stay one step ahead of the evolving resistance. In the 2011 outbreak of Klebsiella, the bacteria evolved resistance even to colistin, a drug of last resort because of its severe side effects.
Over the last 25 years, the number of new antibiotics entering the clinic has drastically declined. At the same time, bacteria have continued to evolve resistance to all of the currently available drugs, creating the current critical situation. One of the main problems in identifying new antibiotics and bringing them to market is a lack of understanding how the molecules work.
“It’s easy to identify thousands of molecules capable of killing bacteria,” explained Kit Pogliano, a professor of biology and a co-author of the paper. “The hard part is picking out the winners from the losers, and choosing molecules that are the best candidates for drug development. One key piece of information needed for this choice is knowledge of how the drug works, but this is traditionally difficult information to obtain, usually requiring months of intensive work. We’ve applied 21st century methods that within just two hours provide this information, allowing more rapid prioritization of new molecules. This will open up the discovery pipeline, allowing us to more rapidly identify new molecules with potential to enter the clinic for treatment of multi-drug-resistant pathogens.”
One key to this new approach was the combination of microscopy and quantitative biology tools. “We had to develop all of the cell biology and quantitative biology methods for generating the data ourselves and that required a lot of work, but now that we have the method working, it is very exciting,” said Poochit Nonejuie, a graduate student in the Division of Biological Sciences and another co-author. “My chemistry colleagues can give me a new molecule in the morning, and by the afternoon I can tell them the likely cellular pathways that they target. It’s mind blowing how powerful the technology is.”
The UC San Diego biologists say their new method is not only game changing, but promises to revolutionize how drug discovery teams guide their studies. With previous methods, understanding how an antibiotic works requires many different biochemical assays to be performed, which requires a lot of time and relatively large quantities of the compound, which is almost always in short supply when it is first discovered.
“Our new method represents the first time that a single test can be performed and identify the likely mechanism of action for a new compound,” said Joseph Pogliano. He noted that postdoctoral fellow Anne Lamsa has miniaturized the method so that it requires just a few nanograms of each drug candidate, conserving molecules that are often available only in tiny quantities.
The Latest Bing News on:
Drug discovery
- Revealing Protein-Ligand Interactions Using AI Enables Drug Discoveryon April 26, 2024 at 7:34 am
Researchers developed a method to assess the ability of small molecules to bind to hundreds of human proteins using AI and ML.
- AI-Driven Drug Discovery by Pfizer and Austrian Institute Set to Transform Healthcareon April 26, 2024 at 5:38 am
Pfizer, the top pharmaceutical firm, and the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM) have developed an AI-driven drug discovery method The novel approach, ...
- This Biotech Startup Aims To Speed Up Drug Testing On Animalson April 26, 2024 at 3:29 am
Gordian Biotechnology’s platform allows for potentially hundreds of gene therapies to be tested in an animal at the same time — without harming it.
- A shortcut for drug discovery: Novel method predicts on a large scale how small molecules interact with proteinson April 25, 2024 at 11:00 am
For most human proteins, there are no small molecules known to bind them chemically (so-called "ligands"). Ligands frequently represent important starting points for drug development but this ...
- UW’s Baker Lab researchers make AI strides in drug-like peptideson April 25, 2024 at 10:59 am
In recent years, artificial intelligence programs for drug design have steadily shown they can help explore far beyond just small-molecule drugs—by illuminating how proteins fold and interact, all | ...
- AI for drug discovery draws a $1 billion launch—and a lot of hopeon April 25, 2024 at 8:20 am
AI's impact on health care is one area where people are more enthusiastic than anxious—and there's reason to think that enthusiasm is not misplaced.
- The Difference Is the Data: Drug Discovery’s AI Revolutionon April 25, 2024 at 4:00 am
New data-intensive platforms continue to leverage artificial intelligence tools for improved speed and failure rate reductions for drug discovery.
- Xaira, an AI drug discovery startup, launches with a massive $1B, says it's 'ready' to start developing drugson April 24, 2024 at 7:17 pm
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture ...
- Enter Xaira, with $1bn for its AI in drug discovery platformon April 24, 2024 at 3:58 am
The San Francisco-based company has emerged from the incubators of ARCH Venture Partners and Foresite Labs with more than $1 billion in funding to develop AI technologies nurtured in the lab of ...
- New AI drug discovery powerhouse Xaira rises with $1B in fundingon April 24, 2024 at 3:00 am
If you asked an AI to generate a brand-new drug discovery biotech with a team of some of the biggest names in the biz for you, it couldn’t dream up one like Xaira Therapeutics. | If you asked an AI to ...
The Latest Google Headlines on:
Drug discovery
[google_news title=”” keyword=”Drug discovery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
New antibiotics
- COVID-19 Worsened overuse of antibiotics, WHO raises concern over dangers of Antimicrobial Resistanceon April 27, 2024 at 5:08 am
The use of antibiotics was highly seen among patients with severe or critical COVID-19, with a global average of 81%.
- FDA Approves New Antibiotic for Uncomplicated UTIson April 26, 2024 at 11:54 am
The US Food and Drug Administration has approved pivmecillinam (Pivya) tablets to treat uncomplicated urinary tract infections in women.
- Common antibiotic Neosporin may shield against viral respiratory infectionson April 26, 2024 at 9:00 am
A study conducted first in mice and then in human volunteers suggests that a common antibiotic, neomycin, which is the main active ingredient in Neosporin, may help protect against viral respiratory ...
- What to Know About Pivya, the New Antibiotic Treatment for UTIson April 26, 2024 at 4:06 am
The Food and Drug Administration recently approved Pivya (pivmecillinam) to treat uncomplicated UTIs in female adults. Clinical trials show that Pivya is effective and side effects are limited.
- Why Doctors Prescribe Older, Less Effective Antibiotics, When New, Less Toxic Treatments Save Liveson April 25, 2024 at 9:00 pm
According to a recent National Institutes of Health (NIH) report, doctors in the United States are still relying on older, less effective, toxic medicines to fight new, highly drug-resistant bacterial ...
- FDA Approves New Antibiotic Against UTIson April 25, 2024 at 7:40 am
"The FDA is committed to fostering new antibiotic availability when they prove to be safe and effective, and Pivya will provide an additional treatment option for uncomplicated UTIs," he added.
- F.D.A. Approves Antibiotic for Increasingly Hard-to-Treat Urinary Tract Infectionson April 24, 2024 at 1:45 pm
Pivmecillinam, which has been used in Europe for decades, will become available next year to women 18 and older.
- Automated Patient Risk Assessment Lowers Antibiotic Prescribing Rateson April 24, 2024 at 10:15 am
Prescriptions for broad-spectrum antibiotics fell when clinicians were intercepted by a risk-assessment prompt.
- AI Hallucinations Are not Always bad – They Can Create New Antibioticson April 24, 2024 at 8:44 am
AI Hallucinations Are not Always bad - They Can Create New Antibiotics. hallucinations are also proving helpful for scientists to discover new drugs.
- New antibiotics aren’t being fully used, study findson April 23, 2024 at 2:02 pm
A new study shows that, despite having newer options for antibiotic-resistant infections, US clinicians are still frequently opting for less optimal older, generic antibiotics.
The Latest Google Headlines on:
New antibiotics
[google_news title=”” keyword=”new antibiotics” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]